Strategic Acquisition The company has recently transitioned through acquisitions (MBio Diagnostics to LightDeck Diagnostics, Heska acquisition in 2023), indicating a strategic shift and potential alignment opportunities with Heska’s veterinary diagnostics channel and existing LightDeck veterinary/environmental tests.

Multiplex Platform LightDeck offers a portable, multiplex fluorescence platform with lab-quality, rapid results (as quick as 5 minutes) and internal quality control, suggesting cross-sell potential to customers needing rapid, point-of-care panels across veterinary, environmental, and human health segments.

Vet Market Focus Current commercialization in veterinary diagnostics presents a ready-made distribution and reference base; expanding to related human and environmental panels could leverage Heska’s veterinary legacy while pursuing adjacent markets.

Expansion Potential Past partnerships with BARDA, DARPA, and SRI indicate strong research collaborations; leverage these relationships to secure government or defense-linked trials and broaden the product portfolio to new indications and regulatory pathways.

Financial Levers Revenue scale and funding indicate a growth phase with room for scaled sales motions; target multi-panel, high-value assays and enterprise licenses to drive higher per-site adoption in clinics, laboratories, and environmental testing facilities.